Fecal microbiota transplantation has become one of the most effective treatments for recurrent Clostridioides difficile infections, but its long-term role in gastroenterology may hinge on moving ...

Researchers examined 72 patients who had at least three bouts of recurrent C. diff in a clinical trial. They treated the patients with fresh, frozen or freeze-dried fecal microbiota transplant ...

Christian John Lillis, cofounder and executive director of the Peggy Lillis Foundation for C difficile Education & Advocacy, explained how FDA-approved microbiome-based therapeutics help to treat and ...

Four things you need to know: 1. A team of researchers led by Michael Bretthauer, MD, PhD, a gastroenterologist at the University of Oslo in Norway, conducted the study at six Norwegian hospitals ...

Ferring Pharmaceuticals’ biotherapeutic passed an FDA committee vote despite some skepticism from a handful of members, setting up the asset for potential approval to treat Clostridioides difficile ...

In the first comprehensive evidence-based guideline on the use of fecal microbiota-based therapies for gastrointestinal disease, the American Gastroenterological Association recommends fecal ...

LA Times Studios produces content by working closely with scientists and healthcare experts as well as sourcing scholarly-reviewed medical and science journals and does not involve the Los Angeles ...

In the first comprehensive evidence-based guideline on the use of fecal microbiota-based therapies for gastrointestinal disease, the American Gastroenterological Association recommends fecal ...

The antibiotic vancomycin, recommended as first-line treatment for infection caused by the deadly superbug C. difficile (C. diff), may not be living up to its promise, according to new research. The ...

Anne J. Gonzales-Luna, research assistant professor in the Department of Pharmacy Practice and Translational Research, University of Houston College of Pharmacy, is reporting the weakening of ...